Tepotinib hydrochloride(1 : x) 是一种口服生物可利用的间充质-上皮转化 (MET) TKI，主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。

Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.

Tepotinib hydrochloride(1 : x) potently inhibits ABCB1 and ABCG2 efflux transporters, which was confirmed by molecular docking. In addition, Tepotinib hydrochloride(1 : x) inhibited several recombinant cytochrome P450 (CYP) isoforms with varying potency. Tepotinib hydrochloride(1 : x) synergistically reversed daunorubicin and mitoxantrone resistance in cells with ABCB1 and ABCG2 overexpression, respectively[2].

1103508-80-0

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years